New drugs in neoadjuvant breast cancer therapy

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent advances in neoadjuvant therapy for breast cancer, including the rationale for the use of the surrogate endpoint, pathological complete response (pCR), for survival in neoadjuvant studies.

Year of Production:
Running Time:
Color/Sound:

2015
03:23
Color/Sound

Comments are closed.